Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mandated label changes?

This article was originally published in The Tan Sheet

Executive Summary

"For me, the FDA has to be given the ability to mandate labeling changes after approval," GlaxoSmithKline Senior VP-Worldwide Development Ronald Krall stated at the meeting. "After appropriate consultation, including experts in the field and the company, FDA needs to be able to say 'enough is enough, here's the labeling.' We don't need this because FDA needs a hammer, but because the public is uncomfortable with how long it takes us to communicate information about our products"...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS099394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel